Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials

详细信息    查看全文

• 作者：Wei Zhang ; Xue-yan Chen ; Su-wen Su ; Qing-zhong Jia ; Tao Ding…
• 关键词：Melatonin ; Neurodegenerative diseases ; Alzheimer disease ; Parkinson disease ; Sleep ; REM sleep behavior disorder
• 刊名：Neurological Sciences
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：37
• 期：1
• 页码：57-65
• 全文大小：1,101 KB
• 参考文献：1.Chen Y, Li S, Su L et al (2015) Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol. doi:10.​1007/​s00415-014-7630-2 PubMedCentral
  2.Reiter RJ (1998) Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56(3):359–384PubMed CrossRef
  3.Pandi-Perumal SR, BaHammam AS, Brown GM et al (2013) Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res 23(3):267–300PubMed CrossRef
  4.Dardente H (2012) Melatonin-dependent timing of seasonal reproduction by the pars tuberalis: pivotal roles for long daylengths and thyroid hormones. J Neuroendocrinol 24:249–266PubMed CrossRef
  5.Cardinali DP, Srinivasan V, Brzezinski A et al (2012) Melatonin and its analogs in insomnia and depression. J Pineal Res 52:365–375PubMed CrossRef
  6.Radogna F, Diederich M, Ghibelli L (2010) Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 80:1844–1852PubMed CrossRef
  7.Scheer FA, Van Montfrans GA, Van Someren EJ et al (2004) Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43:192–197PubMed CrossRef
  8.Guido ME, Garbarino-Pico E, Contin MA et al (2010) Inner retinal circadian clocks and non-visual photoreceptors: novel players in the circadian system. Prog Neurobiol 92:484–504PubMed CrossRef
  9.Dawson D, Armstrong SM (1996) Chronobiotics-drugs that shift rhythms. Pharmacol Ther 69:15–36PubMed CrossRef
  10.Galano A, Tan DX, Reiter RJ (2011) Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 51:1–16PubMed CrossRef
  11.Mediavilla MD, Sanchez-Barcelo EJ, Tan DX et al (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem 17:4462–4481PubMed CrossRef
  12.Reiter RJ, Tan DX, Qi W et al (2000) Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo. Biol Signals Recept 9(3–4):160–171PubMed CrossRef
  13.Ferracioli-Oda E, Qawasmi A, Bloch MH (2013) Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 8(5):e63773PubMed PubMedCentral CrossRef
  14.Raggi A, Ferri R (2010) Sleep disorders in neurodegenerative diseases. Eur J Neurol 17(11):1326–1338PubMed
  15.Higgins JPT, Altman DG, Sterne JAC (Eds.) Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. The Cochrane Collaboration 2011. http://​www.​cochrane-handbook.​org
  16.Paul M, Lador A, Grozinsky-Glasberg S et al. (2014) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1:CD003344
  17.McCleery J, Cohen DA, Sharpley AL (2014) Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev 3:CD009178
  18.Serfaty M, Kennell-Webb S, Warner J et al (2002) Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Intl J Geriatr Psych 17(12):1120–1127CrossRef
  19.Asayama K, Yamadera H, Ito T et al (2003) Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 70(4):334–341PubMed CrossRef
  20.Singer C, Tractenberg RE, Kaye J et al (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in alzheimer’s disease. Sleep 26(7):893–901PubMed PubMedCentral
  21.Dowling GA, Mastick J, Colling E et al (2005) Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 6(5):459–466PubMed CrossRef
  22.Medeiros CA, Carvalhedo de Bruin PF, Lopes LA et al (2007) Effect of exogenous melatonin on sleep and motor dysfunction in parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neuro 254(4):459–64
  23.Dowling GA, Burr RL, Van Someren EJ et al (2008) Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease. J Am Geriatr Soc 56(2):239–246PubMed PubMedCentral CrossRef
  24.Gehrman PR, Connor DJ, Martin JL et al (2009) Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with alzheimer disease. Am J Psychiat 17(2):166–169
  25.Wade AG, Farmer M, Harari G et al (2014) Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging 9:947–961PubMed PubMedCentral
  26.Kunz D, Mahlberg R (2010) A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 19(4):591–596PubMed CrossRef
  27.Lin L, Huang QX, Yang SS et al (2013) Melatonin in Alzheimer’s disease. Int J Mol Sci 14(7):14575–14593PubMed PubMedCentral CrossRef
  28.Rothman SM, Mattson MP (2012) Sleep disturbances in Alzheimer’s and Parkinson’s diseases. NeuroMol Med 14(3):194–204CrossRef
  29.Wu YH, Zhou JN, Van Heerikhuize J et al (2007) Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer’s disease. Neurobiol Aging 28(8):1239–1247PubMed CrossRef
  30.Brusco LI, Fainstein I, Marquez M, Cardinali DP (1999) Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept 8(1–2):126–131PubMed CrossRef
  31.Villa C, Ferini-Strambi L, Combi R (2015) The synergistic relationship between Alzheimer’s disease and sleep disorders: an update. J Alzheimers Dis 46:571–580PubMed CrossRef
  32.Liguori C, Romigi A, Nuccetelli M et al (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 71(12):1498–1505PubMed CrossRef
  33.Polimeni G, Esposito E, Bevelacqua V et al (2014) Role of melatonin supplementation in neurodegenerative disorders. Front Biosci 19:429–446CrossRef
  34.McCarter SJ, Boswell CL, Louis EKS et al (2013) Treatment outcomes in REM sleep behavior disorder. Sleep Med 14(3):237–242PubMed PubMedCentral CrossRef
  35.Howell MJ, Schenck CH (2015) Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol 72(6):707–712PubMed CrossRef
  36.Boot BP (2015) Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther doi:10.​1186/​s13195-015-0128-z
  
• 作者单位：Wei Zhang (1)
  Xue-yan Chen (2)
  Su-wen Su (2)
  Qing-zhong Jia (2)
  Tao Ding (3)
  Zhong-ning Zhu (2)
  Tong Zhang (1)
  
  1. Capital Medical University School of Rehabilitation Medicine, China Rehabilitation Research Center, 10, Jiaomenbei Road, FengTai District, Beijing, 100068, China
  2. Department of Pharmacology, Hebei Medical University, 361, Zhongshan East Road, Shijiazhuang, 050017, China
  3. Department of Pathology, School of Basic Medicine, Hebei University of Chinese Medicine, 3, Xingyuan Road, Luquan, Shijiazhuang, 050200, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Neurology
  Neuroradiology
  Neurosurgery
  Psychiatry
  
• 出版者：Springer Milan
• ISSN：1590-3478

文摘

The purpose of this work is to investigate the efficacy of exogenous melatonin in the treatment of sleep disorders in patients with neurodegenerative disease. We searched Pubmed, the Cochrane Library, and ClinicalTrials.gov, from inception to July 2015. We included randomized clinical trials (RCTs) that compared melatonin with placebo and that had the primary aim of improving sleep in people with neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). We pooled data with the weighted mean difference in sleep outcomes. To assess heterogeneity in results of individual studies, we used Cochran’s Q statistic and the I 2 statistic. 9 RCTs were included in this research. We found that the treatment with exogenous melatonin has positive effects on sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI) in PD patients (MD: 4.20, 95 % CI: 0.92–7.48; P = 0.01), and by changes in PSQI component 4 in AD patients (MD: 0.67, 95 % CI: 0.04–1.30; P = 0.04), but not on objective sleep outcomes in both AD and PD patients. Treatment with melatonin effectively improved the clinical and neurophysiological aspects of rapid eye movement (REM) sleep behavior disorder (RBD), especially elderly individuals with underlying neurodegenerative disorders. This meta-analysis provided some evidence that melatonin improves sleep quality in patients with AD and PD, and melatonin can be considered as a possible sole or add-on therapy in neurodegenerative disorders patients with RBD.